Health Condition 1: C920- Acute myeloblastic leukemia
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Tata Research Administrative Council TRAC
Eligibility
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed AML and high-risk myelodysplastic syndrome. 2. Planned treatment with Cytarabine and daunomycin with or without midostaurin 3. Normal organ function and no active infection in lungs 4. Accommodation facility within one hour distance from hospital.
Exclusion criteria
Exclusion criteria: 1. platelet count less than 10000 after 1 unit SDP transfusion 2. Clinical internal/visceral bleeding manifestations like hematemesis, melaena, hematuria 3. History of hypersensitivity/ allergy to blood/ blood products, chemotherapeutic drugs and antibiotics 4. Acute medical emergencies like diabetic ketosis, diabetic ketoacidosis, hypertensive urgency/ emergency, acute kidney injury etc 5. Relapsed AML case patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate Induction mortality- death within 4 weeks after starting AML inductionTimepoint: 28 days | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To access complete remission rates and readmission rates. To decrease the time from diagnosis of AML to treatment initiation. Incidence of noncompliance among the OPD follow up patients with regard to scheduled visit follow up. To access progression free survival at 2 yearsTimepoint: 2 years | — |
Countries
India
Contacts
Public ContactDr Hasmukh Jain
Tata Memorial Centre
Outcome results
None listed